BridgeBio Pharma, Inc. — Director's Dealing 2025

Jun 11, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2025-06-10

Reporting Person: Valantine Hannah (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-06-10	Common Stock	M	4292	$16.75	Acquired	6056	Direct
2025-06-10	Common Stock	S	4292	$40	Disposed	1764	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-06-10	Stock Option (right to buy)	$16.75	M	4292	Disposed	2033-06-21	Common Stock (4292)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	3433	Indirect

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 5, 2024.

F2: The stock option vests and becomes exercisable in three annual installments starting on June 22, 2023 and ending on June 22, 2025, subject to the Reporting Person's continued service on the Issuer's Board of Directors.